{
    "clinical_study": {
        "@rank": "25072", 
        "arm_group": {
            "arm_group_label": "Glaucoma", 
            "description": "Patients with open-angle glaucoma (OAG) that require topical intraocular pressure lowering therapy and that were scheduled to switch current therapy to preservative-free DTFC."
        }, 
        "brief_summary": {
            "textblock": "This study aims at validating in real-life clinical practice and using the self-reported\n      Glaucoma Symptom Scale (GSS) questionnaire, the impact of a switch to preservative-free\n      dorzolamide/timolol fixed combination (DTFC) in patients using preserved topical therapy for\n      glaucoma."
        }, 
        "brief_title": "Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Open Angle Glaucoma", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is an 8-week multi-center, prospective, observational and non-interventional,\n      open-label study aiming at assessing a change in visual-related quality of life of glaucoma\n      patients that switch therapy to preservative-free DTFC. As a non-interventional study, the\n      decision for the to switch was at the discretion of the physician. Patients scheduled to\n      switch therapy to preservative free DTFC will be asked to fill in the 10 item, linkert-type\n      GSS questionnaire at baseline, at week 4 and at week 8 of therapy switch.\n\n      The study data will be collected at a baseline and at 2 follow-up visits occurring 4 weeks\n      +/- 1 week and 8 weeks +/- 1 week. If no visit was scheduled, the patient was asked to send\n      the completed documents to the physician."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults patients aged over 18 years old at inclusion visit\n\n          -  Diagnosed as having OAG in one or both eyes\n\n          -  Who have used the previous preserved eye drops treatment for at least 4 weeks in one\n             eye or both eyes\n\n          -  Experiencing pre-established ocular surface disease symptoms, as defined in the 2007\n             report of the International Dry Eye Workshop\n\n          -  Being scheduled by their ophthalmologist for a switch to preservative-free DTFC eye\n             drops (as monotherapy or replacement of one preserved product of a combined therapy)\n             at inclusion visit due to tolerability issues\n\n          -  Accepting to participate in the study and who has provided a written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients who had filtering or other ocular surgery within the 6 months preceding the\n             inclusion visit\n\n          -  Who have already been treated with preservative-free DTFC\n\n          -  Whose visual acuity is importantly impaired by a severe ocular disease other than\n             OAG, as assessed by the physician\n\n          -  Currently involved in a clinical trial or study cohort or pharmaco-epidemiology study\n             or interventional study\n\n          -  With serious mental or physical disability which could interfere with a\n             patient-reported assessment\n\n          -  Pregnant women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with OAG that require topical therapy for intraocular pressure lowering and that\n        were scheduled to switch current therapy to preservative-free DTFC"
            }
        }, 
        "enrollment": {
            "#text": "103", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923714", 
            "org_study_id": "S-53534"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Timolol", 
                "Dorzolamide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Glaucoma", 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "state": "Flemish Brabant", 
                    "zip": "B-3000"
                }, 
                "name": "University Hospitals Leuven"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms in Belgian Glaucoma Patients", 
        "overall_official": {
            "affiliation": "UZ Leuven", 
            "last_name": "Ingeborg Stalmans, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The main study objective was to assess a change in the patient-reported Glaucoma Symptom Scale questionnaire, filled in at baseline (Week 0) and at the end of the 8 week of therapy with preservative-free DTFC.", 
            "measure": "Change in Glaucoma Symptom Scale questionnaire", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923714"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "A secondary outcome was to assess a change in the patient-reported Glaucoma Symptom Scale questionnaire functional parameters, filled in at baseline (Week 0) and week 4 and week 8 of therapy with preservative-free DTFC.", 
                "measure": "Change in Functional-related items of the Glaucoma Symptom Scale", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "A secondary outcome was to assess a change in the patient-reported Glaucoma Symptom Scale questionnaire symptomatic parameters, filled in at baseline (Week 0) and week 4 and week 8 of therapy with preservative-free DTFC.", 
                "measure": "Change in Symptom-related items of the Glaucoma Symptom Scale", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2012"
    }
}